Pharmosa Biopharm Inc.(6875 TT) develops existing drugs by exploiting innovative delivery formulations and medical devices, then bringing combined medicines to patients and healthcare providers. Its first new drug has entered phase III clinical trials and is expected to apply for FDA approval in two years.

CDIB Capital Management. Main Business Line. Private Equity Investments and Related Advisory Services ... With an industry-leading international team, we play a pivotal leading role in Taiwan's venture capital and private equity markets. This website uses cookies to offer you the best services. By continuing to browse or by clicking Accept, you ...

With an industry-leading international team, we play a pivotal leading role in Taiwan's venture capital and private equity market. Our Leadership Team. ... Chair of Regional Healthcare Practice at CDIB Capital Group: James Ho: Supervise asset management and investment management related to Healthcare sector:

CDIB Capital Healthcare Ventures II led the series B funding round for Acepodia and helped the company successfully raise US$47 million in a very short period of time. Professional Capital Market Experience. Even during phases of market volatility, our vast resources and experience in the capital market get our partners results. ...

Venture and Growth Capital. Overview. Strategies . Overview. Venture ... Healthcare Strategies . We focus on high-potential startups in biotech and pharmaceuticals, med-tech, and digital health care industries, along with broader biomedical and healthcare service sectors. ... leveraging on CDIB Capital’s direct investment expertise and the ...

CDIB Capital Group (CDIB) is pleased to announce that it has completed an investment in Dr. Andrew Ng’s AI Fund, a venture studio based in Silicon Va... learn more Jan 24, 2025

CDIB Capital Healthcare Ventures’ AUM exceeds NT$10bn Healthcare Fund II oversubscribed, to kick off investment in September. Jul 14, 2020. Press Release. CDF announces preliminary June earnings of NT$986mn, 1H20 accumulative earnings of NT$3.03bn, for EPS of NT$0.21. Jul 10, 2020.

China Development Industrial Bank was officially renamed CDIB Capital Group with this underlying business transformation in March 2017. This evolution is underpinned by the goal of becoming the leading private equity and venture capital fund manager in the Asia-Pacific region.

Founded in 1982, PT MedTech is a total solution contract manufacturer of cable and wire harness assemblies, components, sub-assemblies and final assemblies for medical devices in China, directly serving a solid and entrenched customer base consisting of Fortune 500 corporates, multinational medical device suppliers, emerging medical technology companies, and specialized provider of surgical ...

CDIB Capital Healthcare Ventures’ Portfolio Company ACT Genomics Establishes Molecular Laboratory for International Customers in Asia. CDIB will continue to promote the industry investment chain to help Taiwan’s biotechnology industry reach the global stage. Oct 18, 2021.